Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

08.08.24	Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook (RTTNews)
08.08.24	Eli Lilly Again Boosts FY24 Outlook - Update (RTTNews)
08.08.24	Eli Lilly And Co. Q2 Profit Increases, Beats Estimates (RTTNews)
08.08.24	Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion (EN, Eli Lilly)
04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
01.08.24	Lilly Reports Positive Topline Results From SUMMIT Phase 3 Study Of Tirzepatide (RTTNews)
01.08.24	Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity (EN, Eli Lilly)
25.07.24	Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement (EN, Eli Lilly)
17.07.24	Aclaris Sells OLUMIANT Royalties & Milestones To OMERS For Up To $31.5 Mln; Stock Up In After-hours (RTTNews)
08.07.24	Lilly To Acquire Morphic In Approx. $3.2 Bln Deal - Quick Facts (RTTNews)
08.07.24	Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease (EN, Eli Lilly)
03.07.24	FDA Approves Lilly's Kisunla To Treat Early Symptomatic Alzheimer's Disease (RTTNews)
02.07.24	Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease (EN, Eli Lilly)
25.06.24	Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials (RTTNews)
25.06.24	Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria (EN, Eli Lilly)
24.06.24	Lilly Declares Third-Quarter 2024 Dividend (EN, Eli Lilly)
21.06.24	Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution (EN, Eli Lilly)
20.06.24	Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products (EN, Eli Lilly)
20.06.24	An Open Letter From Eli Lilly and Company Regarding Certain Practices Related to Mounjaro® and Zepbound® (EN, Eli Lilly)
08.06.24	Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks (EN, Eli Lilly)
05.06.24	Eli Lilly CFO Anat Ashkenazi Resigns (RTTNews)
05.06.24	Lilly announces departure of Anat Ashkenazi, chief financial officer (EN, Eli Lilly)
04.06.24	Melissa Seymour to join Lilly as executive vice president of Global Quality (EN, Eli Lilly)
01.06.24	Lilly Announces Updated Data From Phase 1/2 Study Of Olomorasib In Advanced Solid Tumors (RTTNews)
01.06.24	Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting (EN, Eli Lilly)
30.05.24	Biotech Stocks Facing FDA Decision In June 2024 (RTTNews)
29.05.24	Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases (EN, Eli Lilly)
28.05.24	Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (EN, Eli Lilly)
24.05.24	Lilly Increases Investment In Indiana-Based Unit To Enhance Production Of Zepbound, Mounjaro (RTTNews)
24.05.24	Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines (EN, Eli Lilly)
23.05.24	Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (EN, Eli Lilly)
21.05.24	Lilly Reports Positive Phase 3 Trial Results Of Mirikizumab In Crohn's Disease (RTTNews)
21.05.24	More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure (EN, Eli Lilly)
16.05.24	Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint (RTTNews)
16.05.24	With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin (EN, Eli Lilly)
15.05.24	Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer (EN, Eli Lilly)
14.05.24	Lilly Update on Mounjaro® and Zepbound® (tirzepatide) Compounding Litigation (EN, Eli Lilly)
07.05.24	FDA Advisory Committee To Convene Meeting To Discuss On Eli Lilly's Alzheimer's Drug (RTTNews)
07.05.24	Lilly Statement on FDA Advisory Committee Meeting on Donanemab for Early Symptomatic Alzheimer’s Disease (EN, Eli Lilly)
06.05.24	Lilly Declares Second-Quarter 2024 Dividend (EN, Eli Lilly)
30.04.24	Eli Lilly Boosts FY24 Outlook - Update (RTTNews)
30.04.24	Eli Lilly And Co. Q1 Profit Increases, beats estimates (RTTNews)
30.04.24	Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum (EN, Eli Lilly)
26.04.24	Lilly Recommends Shareholders Reject “Mini-Tender” Offer by Tutanota LLC (EN, Eli Lilly)
22.04.24	Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals (EN, Eli Lilly)
17.04.24	Eli Lilly's Weight Loss Drug Zepbound Shows Promise In Reducing Sleep Apnea (RTTNews)
17.04.24	Lilly's Tirzepatide To Treat Sleep Apnea Meets Primary Goals In Late-stage Studies (RTTNews)
17.04.24	Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity (EN, Eli Lilly)
16.04.24	Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement (EN, Eli Lilly)
11.04.24	Roche's Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimer's Detection (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:06		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
15:58		Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer
15:58		Anleger in Frankfurt halten sich zurück: LUS-DAX liegt nachmittags im Minus
15:58		Donnerstagshandel in Frankfurt: DAX mit Kursplus

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:56

Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an

16:06

Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa

15:58

Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer